#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Cryopreservation of hematopoietic cells from unrelated donors from the Czech National Bone Marrow Donor Registry in the context of COVID-19 pandemic – are there useless collections?


Authors: K. Steinerová 1,2;  P. Jindra 1,2;  L. Houdová 3
Authors‘ workplace: Hematologicko-onkologické oddělení, FN Plzeň 1;  Český Národní Registr Dárců Dřeně, Plzeň 2;  NTIS – Nové technologie pro informační společnost, Fakulta aplikovaných věd, Západočeská univerzita v Plzni 3
Published in: Transfuze Hematol. dnes,30, 2024, No. 3, p. 169-174.
Category: Original Papers
doi: https://doi.org/10.48095/cctahd2024prolekare.cz14

Overview

One of the responses the COVID-19 pandemic has been a worldwide increase the number of cryopreserved hematopoietic cells from unrelated donors, mainly due to poorer availability of donors and problems with product transportation. Although cryopreservation is logistically advantageous, the higher risk of not using graft cannot be ignored. We retrospectively evaluated the cryopreservation of donors from the Czech National Register of Bone Marrow Donors (CNMDR) in the period before, during and after the COVID-19 and analyzed unused grafts, including the reasons. The primary goal was to evaluate how cryopreserved grafts collected in given periods for transplant centers (TC) in the Czech Republic and abroad has changed. Of the total number of 374 grafts collected in the period 2018–2023, 72 (19%) were cryopreserved. In the period before the pandemic (2018–2/2020), 152 grafts collected and only 2 cryopreservations performed (1.3%), 1 for TC in the CR and 1 for foreign. During the period of the COVID-19 pandemic (3/2020–2022), a total of 144 grafts collected, 58 cryopreserved (40%), 28 (19%) for patients from CR and 20 (14%) for forein. In the post-pandemic (year 2023), 78 grafts taken, 22 cryopreserved (28%), 8 (10%) for patients from CR and 14 (18%) for patients from abroad. For period 2018–2023, 3 grafts (0.8%) were not used, all from the period of COVID-19 (1 from 2020 and 2 from 2022) and were collected for patients from foreign TCs. The reason for not-used grafts was in 2 cases death of the patient and 1 patient refused transplant. Our analysis shows a decrease in cryopreserved grafts in the post-pandemic period for patients from CR, while for patients from foreign TCs continues to show a slightly upward trend. Despite the detected low percentage of unused grafts, it is necessary to perceive the negative ethical impact of the destruction of the graft from the point of view of the donors.

Keywords:

registry – Cryopreservation – donor


Sources
1. Devine SM. Transplantation of allogeneic cryopreserved hematopoietic cell grafts during the COVID‐19 pandemic: a National Marrow Donor Program perspective. Am J Hematol. 2021; 96 (2): 169–171.
2. Bankova AK, CaveneyJ, Yao B, et al. Real-world experience of cryopreserved allogeneic hematopoietic grafts during the COVID-19 pandemic: a single-center report. Transplant Cell Ther. 2022; 28 (4): 215.
3. Hsu JW, Farhadfar N, Murthy H, et al. The effect of donor graft cryopreservation on allogeneic hematopoietic cell transplant outcomes: a CIBMTR analysis. implications during The COVID-19 pandemic. Transplant Cell Ther. 202; 27 (6): 507–516.
4. Pawson R, Anthias C, Cody M, et al. Serious stem cell donation events and recipient adverse reactions related to severe acute respiratory syndrome coronavirus 2: review of Reports to the World Marrow Donor Association. Transplant Cell Ther. 2023; 29: 522.e1–522.e5.
5. Fernandez-Sojo J, Azqueta C, Valdivia E, et al. Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic? Bone Marrow Transplant. 2021; 56 (10): 2489–2496.
6. Fernandez-Sojo J, Horton R, Cid J, et. al. Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry. Bone Marrow Transplant. 2022; 57 (10): 1531–1538.
7. Jöri MM, Schmidt AH, Bernas SN, et al. Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020 – report from World Marrow Donor Association. Bone Marrow Transplant. 2022; 57 (6): 1021–1024.
8. Farhadfar N, Newman J, Novakovich J, et al. Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: a report from the National Marrow Donor Program. Front Immunol. 2022; 13: 20.
9. Othman J, Aarons D, Bajel A, et al. Allogeneic haemopoietic cell transplant services in Australia and New Zealand in the first year of the COVID-19 pandemic: a report from Australia and New Zealand transplant and cellular therapies. Intern Med J. 2023; 53 (3): 323–329.
10. DKMS. [online]. Available from: https: //professional.dkms.org/about/stem-cell-bank (accessed on March 15, 2024).
PODÍL AUTORŮ NA RUKOPISU
KS – příprava studie, organizace sběru dat, napsání rukopisu
PJ – návrh studie, připomínkování rukopisu, konečná kontrola rukopisu
LH – organizace sběru dat, statistické zpracování
PODĚKOVÁNÍ
Všem pracovníkům dárcovských a náběrových center, všem spolupracovníkům registru, všem spolupracovníkům ze Západočeské univerzity a všem dárcům.
Do redakce doručeno dne: 25. 3. 2024.
Přijato po recenzi dne: 25. 4. 2024.
MUDr. Kateřina Steinerová
Hematologicko-onkologické oddělení
FN Plzeň
alej Svobody 80
304 60 Plzeň
&
Český národní registr dárců dřeně
Na Roudné 123/212
301 00 Plzeň
e-mail: steinerovak@fnplzen.cz
Labels
Haematology Internal medicine Clinical oncology

Article was published in

Transfusion and Haematology Today

Issue 3

2024 Issue 3

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#